Editor's Choice Paper: A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study

Editorial Paper: Sunset, or dawn of a new age for ovarian cancer vaccine therapy?

Hosted by: Dr. Barbara Goff, Deputy Editor

Featuring: Dr. O'Cearbhaill, Dr. Jazaeri, Dr. Goff